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Abstract It is well established that variations in genes
can alter the pharmacokinetic and pharmacodynamic pro-
file of a drug and immunological responses to it. Early
advances in pharmacogenetics were made with traditional
genetic techniques such as functional cloning of genes
using knowledge gained from purified proteins, and can-
didate gene analysis. Over the past decade, techniques for
analysing the human genome have accelerated greatly as
knowledge and technological capabilities have grown.
These techniques were initially focussed on understanding
genetic factors of disease, but increasingly they are helping
to clarify the genetic basis of variable drug responses and
adverse drug reactions (ADRs). We examine genetic
methods that have been applied to the understanding of
ADRs, review the current state of knowledge of genetic
factors that influence ADR development, and discuss how
the application of genome-wide association studies and
next-generation sequencing approaches is supporting and
extending existing knowledge of pharmacogenetic pro-
cesses leading to ADRs. Such approaches have identified
single genes that are major contributing genetic risk factors
for an ADR, (such as flucloxacillin and drug-induced liver
disease), making pre-treatment testing a possibility. They
have contributed to the identification of multiple genetic
determinants of a single ADR, some involving both phar-
macologic and immunological processes (such as pheny-
toin and severe cutaneous adverse reactions). They have
indicated that rare genetic variants, often not previously
reported, are likely to have more influence on the pheno-
type than common variants that have been traditionally
tested for. The problem of genotype/phenotype discordance
affecting the interpretation of pharmacogenetic screening
and the future of genome-based testing applied to ADRs
are also discussed.
Key Points
Adverse drug reactions can often result from
underlying genetic factors.
Human genomes harbour many rare genetic variants
that may contribute to unusual drug responses or
adverse drug reactions.
The application of modern genomic methods such as
genome-wide association studies and next-
generation sequencing is helping to clarify these
genetic risk factors.
As generation of genomic data becomes more
routine in the clinical setting, knowledge of genetic
variation that contributes to adverse drug reactions
could be of predictive value, even for adverse drug
reactions that are rare.
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1 Introduction
The variability between individuals in their response to
drugs has been recognised for several decades. Historically,
pharmacogenetic effects were noted as early as 510 B.C.
when Pythagoras noted that ingestion of fava beans resul-
ted in the acute sickness and death of some individuals [1].
Twenty centuries later, it was discovered that a defect in
the glucose-6-phosphate dehydrogenase enzyme was
associated with haemolytic anaemia after exposure to fresh
fava beans or drugs such as primaquine, aspirin or phena-
cetin [1]. This discovery was followed by the characteri-
sation of genetic variation in the pseudocholinesterase
enzyme underlying the prolonged response to choline
esters during anaesthetic induction [2, 3], and later the
genetic variation in acetylator enzymes resulting in vari-
able response to the drug isoniazid [4]. The discovery of
polymorphic cytochrome P450 enzyme (CYP)2D6, was not
until the late 1970s [5, 6] to late 1980s when mutations
associated with debrisoquine metabolism were charac-
terised [7, 8]. These genetic variants caused changes in the
pharmacokinetic or pharmacodynamic profile of a drug,
therefore impacting efficacy and often resulting in drug-
induced toxicity [7].
Our understanding of genetic factors that underpin
adverse drug reactions (ADRs) has grown through the last
few decades as genetic technologies have become
increasingly sophisticated. Although the primary focus of
these technologies has been the mapping, identification and
analysis of genes that contribute to disease, these tools
have also been applied to explore the variability in human
drug responses. Pharmacogenetics, like human genetics in
general, began with the analysis of traits encoded by a
single gene, simply because such traits were more amen-
able to study. These traits, referred to as being monogenic
or Mendelian in nature, arise from mutation of a single
causative gene, and they generally display clear familial
inheritance patterns. One example of such a Mendelian
pharmacogenetic trait is the ryanodine receptor mutations
that cause malignant hyperthermia after administration of
general anaesthetics, in an autosomal dominant fashion
(meaning only one copy of the gene, or allele, need be
mutated) [9, 10]. However, we now recognise that rela-
tively few traits are truly monogenic, and most result from
the interaction of many genetic and environmental factors.
Most common diseases and other phenotypes such as
height and weight fall into this category, and we refer to
these as complex traits. There is increasing evidence that
many drug responses are also complex traits. Although we
have yet to completely describe the genetic architecture of
any complex human trait, it is clear that in general many
genes, each of small effect size, contribute to such phe-
notypes (Fig. 1).
2 Genetic Technologies and ADRs
2.1 Linkage Mapping
One of the most productive early methods for exploring
monogenic traits was linkage analysis, which involved
tracking the pattern of inheritance of DNA markers within
families displaying the trait or disease, to map the location
of the underlying causative gene [11]. Although a very
productive approach in studies of human genetic disease
[12], linkage mapping has not been an avenue widely
available for pharmacogenetic studies simply because it is
rare for pharmacogenetic phenotypes to be defined in all
members of large families. Even those ADRs that may
result from the effect of a single major gene will often not
be recognised as such, unless multiple members of a family
have been exposed to the same or similar drugs.
2.1.1 Early Genetic Studies on ADRs
Despite the inability to widely apply linkage methods to the
analysis of pharmacogenetics, some important early
advances were made using functional candidate gene
analysis, where variation in genes functionally linked to the
relevant phenotype were studied in groups of subjects. For
example, the debrisoquine/sparteine metabolism pheno-
type, which essentially behaves as a monogenic trait, was
first observed in individuals [5, 6], then further charac-
terised using a gene cloning and identification method that
depended on an understanding of the function of the gene
of interest, leading to the description of CYP2D6 and the
main poor metaboliser variants [7, 8].
Similarly, the thiopurine methyltransferase (TPMT)
gene was isolated after purification and amino-acid
sequencing of the protein, which provided information that
led to molecular cloning of the gene [13, 14]. Neither of
these classic pharmacogenes, which can contribute to
ADRs, was identified in linkage studies, although the
phenotypes they caused were recognised to track within
families. Rather, detailed prior pharmacological investi-
gation was required to pinpoint the relevant protein, which
then led to isolation of the genes.
Such candidate gene studies, where ‘‘educated guesses’’
of genes likely to underpin a phenotype, were the pre-
dominant approach in genetics and pharmacogenetics [15,
16] until the advent of genome-wide association studies
(GWAS) [17–19].
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2.1.2 Genome-Wide Association Studies
GWAS have enabled the precise and effective discovery of
genes underpinning complex diseases and traits, including
drug treatment responses [20, 21]. These studies require the
high-throughput analysis of single nucleotide polymor-
phisms (SNPs), i.e., variations in single base pairs,
throughout the genome. SNPs can impact the way a protein
is coded in a particular gene, the way it is spliced,
expressed, or regulated. When these changes occur in
genes coding for enzymes, transporters, cell membrane
receptors, intracellular receptors, or components of ion
channels, they may change the pharmacokinetic or phar-
macodynamic profile of a drug, affecting its efficacy and its
likelihood of causing ADRs [22, 23]. These SNPs are
catalogued by unique identifiers (called Reference SNP
cluster ID, or ‘‘rs’’ numbers, as listed in Table 1) [24].
GWAS methodology was made possible by the con-
vergence of several lines of investigation. First, the efforts
directed at cataloguing human genetic variation, particu-
larly SNPs, allowed development of very rich maps
illustrating the correlations (linkage disequilibrium)
between alleles of SNPs in the human genome [25, 26].
Second, commercial interests led to the development of
several platforms for massively parallel analysis (geno-
typing) of SNPs on ‘‘gene chips’’. Third, the mathematical
and computational tools necessary for processing the very
large datasets generated by genotyping many thousands of
SNPs in hundreds or thousands of subjects were devel-
oped [27]. One further factor was essential for the success
of GWAS. It became increasingly clear that for truly
complex traits, large cohorts of cases and controls would
be needed to identify the many genes of small effect
underlying each trait; this realisation drove extensive
international collaborations on human complex disease
studies, in a way not previously seen in biomedical sci-
ence [28].
Since the first application of GWAS technology [29],
over 2000 genes contributing to complex traits have been
identified using this method [20, 21]. Although the primary
application of GWAS has been to the understanding of
human diseases and other complex traits, the method has
been increasingly employed to study the genetics of drug
responses and adverse drug reactions [22, 30, 31]. A major
challenge for the application of GWAS to ADRs is the
problem of collecting sufficient samples, given the rarity of
these phenotypes. This requires concerted international
collection and aggregation of samples, such as is being
mediated by the International Serious Adverse Events
Consortium [32], EUDRAGENE [33], and other national
and international consortia [34, 35]. One of the surprises
resulting from the application of GWAS to ADRs has been
that even with small numbers of subjects relative to those
needed for studies of complex disease, single genes have
Fig. 1 Monogenic and complex
traits. Monogenic traits arise
from mutation of a single gene,
and usually display clear
familial patterns of inheritance,
reflecting whether the trait
occurs when one allele
(dominant) or both alleles
(recessive) are disrupted.
Complex traits arise from the
input of polymorphic variation
in several to many genes, each
of which contributes a small
effect to the trait. Complex traits
have some degree of familiality,
but do not display the classical
patterns of inheritance seen in
monogenic traits. Modified from
[165]
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been clearly identified as contributing risk factors for some
ADRs. Good examples are the association of variants in
SLC01B1, the gene for the organic anion-transporting
polypeptide OATP1B1, with statin-induced myopathy [36],
and the association of human leukocyte antigen (HLA)-
B*5701 variants with drug-induced liver injury (DILI)
from flucloxacillin [37].
As well as discovering genetic variants underpinning
several ADRs, GWAS have also extended existing
knowledge of pharmacogenetic processes. For example,
in warfarin dose response, variants of VKORC1 and
CYP2C9 had long been recognised as major factors.
GWAS initially confirmed the role of these two genes [38]
and then revealed an additional gene, CYP4F2, with a
relatively minor role [39]. The range of GWAS studies
now published in pharmacogenetics makes it clear that
technology is no longer the main limiting factor for
understanding genetic factors influencing ADRs [22, 30],
but rather it is often the timely identification, consenting
and collection of subjects to add into such studies that
limits progress.
2.1.3 Next-Generation Sequencing Methods
Over the past decade, methods for DNA sequencing have
undergone dramatic improvements. These methods,
appropriately named next-generation sequencing (NGS)
technologies, have vastly increased the scale of DNA
sequencing while also reducing the unit cost [40, 41].
Although the first human genome project took over a
decade and cost some USD 3 billion, NGS advances now
mean that a human genome can be sequenced in a few
hours for less than USD $2000.
Although whole genome sequencing (WGS) is now
possible [42, 43], the datasets that result and the processing
power required to effectively analyse them, means that
they have not yet been widely employed. Instead, analysis
of only a subset of the genome, known as the exome, has
been the preferred method for many initial studies [44]
(Fig. 2). The exome spans all exons, or protein coding
regions, of an individual’s DNA, and the process of whole
exome sequencing (WES) allows physical ‘‘capture’’ and
then sequencing of most exons from an individual in one
NGS work flow. Application of WES means that variations
in protein-coding regions of any gene can be identified,
rather than focusing on one or a few genes as in traditional
candidate gene studies [44, 45]. Although it has been a very
informative technology, WES has some significant limita-
tions, the most important of which is its inability to identify
variants located outside of exons, in regulatory regions
(introns), or in regions not known to be associated with any
genes [46, 47]. In addition, exome data are not well suited
to the identification of major structural variations seen in
the genome, known as copy number variations. These
limitations, combined with the recent availability of newer
massive-throughput DNA sequencers, mean that WGS is
gaining in popularity and this, rather than WES, may soon
become the dominant approach for genome analysis [48].
Below we summarise current knowledge of genetic loci
that have been identified as significant pharmacogenetic
markers for pharmacokinetic or pharmacodynamic drug
profiles or individual immunologic responses to drugs
leading to ADRs. Where available, we will identify
advances in pharmacogenomics that have arisen through
application of the newer genetic technologies, including
GWAS and NGS.
Table 1 Common CYP2D6
variants. Table modified from
[53, 156]
Allele Major nucleotide variation dbSNP number Effect on CYP2D6 protein
*1 Wild type
*xN Gene duplication or multiplication Increased protein expression






*5 Gene deletion N/A Gene deletion—protein not expressed
*6 1707delT rs5030655 aFrameshift—protein not expressed











a Frameshift mutations either insert or delete one or more bases so that the correct protein is no longer
produced
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3 Drug-Metabolising Enzymes
The initial focus of pharmacogenetics was the polymor-
phisms affecting drug-metabolising enzymes (DMEs). Up
to 60 % of all drug-induced toxicity is associated with
polymorphic CYPs, also referred to as ‘phase one
enzymes’ [49]. The CYP gene superfamily account for the
majority (86 %) of all DMEs. Polymorphisms in CYP
genes result in four major phenotypes with respect to drug
metabolism, poor metaboliser, intermediate metaboliser,
extensive metaboliser or ultra-rapid metaboliser. A partic-
ular polymorphism may therefore result in therapeutic
failure or toxicity, with a reverse effect if the drug is a pro-
drug [50].
Although to date there are relatively few publications
that use NGS methods to investigate drug-induced ADRs
and associations with variants in CYP enzymes, a study by
Gordon et al. applied targeted NGS of multiple genes from
over 14,000 subjects, to illustrate the extent of potentially
deleterious variation in 12 CYP genes. The authors focus-
sed on a set of 12 CYP genes that they described as being
responsible for 75 % of all drug metabolism through oxi-
dation reactions [51]. A total of 219 likely functional
variants across 12 CYP genes were discovered, and variants
were found to be abundant, occurring at an average of one
per 17 bases sequenced [51].
Below we summarise clinically important polymor-
phisms affecting widely used drugs metabolised by
CYP2D6, CYP3A4, CYP2C9 and CYP2C19.
3.1 CYP2D6
The gene coding the CYP2D6 enzyme is one of the best
studied pharmacogenes. Approximately 25 % of all drugs,
including a number of antidepressants, anti-arrhythmics,
beta-blockers, opioid analgesics and anti-cancer agents, are
metabolised through CYP2D6, which also happens to be
one of the most polymorphic enzymes with over 100
known allelic variants. A 20-fold inter-individual variation
in steady-state plasma concentrations of nortriptyline, a
substrate for CYP2D6, following a standard daily dose
over 2 weeks, was first reported in 1967 [52]. It is now
Fig. 2 The evolution in genomic technologies. Pharmacogenetic
analysis has evolved from analysing one gene (in a few patients) and a
few single nucleotide polymorphisms (SNPs) in a candidate gene
study, to genome-wide association studies (GWAS), which look
through a library of up to a million SNPs in groups of patients by
using high-throughput genotyping systems (referred to as a SNP chips
or SNP array). Next-generation sequencing has now taken a further
step by enabling researchers to sequence the protein coding part of the
genome (approximately 1 %)—whole exome sequencing (WES), or
even the entire genome—whole genome sequencing (WGS)
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known that polymorphisms in the CYP2D6 gene can result
in a range of effects from complete loss of enzyme activity
through deletion of the gene (poor metaboliser status), or
extensive activity, through duplication of the gene (ultra-
rapid metaboliser status) [50]. Common CYP2D6 variants
are shown in Table 1.
Commonly prescribed analgesics such as codeine,
dihydrocodeine, tramadol and morphine, are largely
metabolised through hepatic CYP2D6. The Clinical Phar-
macogenetics Implementation Consortium (CPIC) guide-
lines for codeine recommend using alternative analgesics
in patients who have been genotyped as ultra-rapid
metabolisers (an individual carrying more than two
functional alleles) or poor metabolisers (an individual
carrying no functional CYP2D6 alleles) [53]. Ultra-rapid
metabolisers are likely to excessively metabolise the parent
compound, in the case of codeine to morphine resulting in
ADRs ranging from mild nausea, vomiting and drowsiness
to more severe, but rare circulatory depression, shock or
cardiac arrest [53–55]. In contrast, poor metabolisers have
low codeine-morphine conversion and complain of poor or
no analgesia [56, 57]. The CPIC has also recommended
that poor and ultra-rapid metabolisers use morphine and
non-opioid analgesics instead of tramadol, oxycodone and
hydrocodone, as their metabolism is also affected by
CYP2D6 polymorphisms [58].
A large proportion of antidepressant and antipsychotic
drugs are metabolised predominantly through the activity
of CYP2D6. CPIC dosing guidelines are currently avail-
able for several such drugs, mostly tricyclic antidepres-
sants. These guidelines recommend a 25–50 % reduction in
dose for intermediate-poor metabolisers, and an alternative
drug for ultra-rapid metabolisers [59]. Studies conducted in
patients taking amitriptyline showed that CYP2D6 poor
metaboliser status resulted in impaired drug metabolism,
hence elevated amitriptyline plasma concentrations and an
increased risk of ADRs, discontinuation of therapy or
switching to another drug [60, 61]. According to the cat-
alogue of published GWAS [62], a study in 435 patients
with major depressive disorder found single nucleotide
polymorphisms in the CYP2D6 and CYP2C19 genes to be
significantly associated with measured plasma concentra-
tions of citalopram, escitalopram and their metabolites
[63].
A difference in the CYP2D6*4 allele frequency was
noted between 75 patients with atorvastatin-related
myopathy and 188 atorvastatin-tolerant controls and
between 61 patients with simvastatin-related myopathy and
188 controls although the difference was only significant
for atorvastatin. Other studies have not confirmed this
association but the possible effect on a particular statin may
have been masked by several statins being studied as a
group [59].
3.2 CYP3A4
Compared with CYP2D6, CYP3A4 is responsible for the
metabolism of a greater proportion of drugs, up to
50–60 %, but is ‘‘strongly conserved’’, meaning that the
CYP3A4 gene is not as polymorphic as the CYP2D6 gene.
While several polymorphisms within the CYP3A4 gene
have been identified, current consensus is that SNPs
affecting this gene generally have minimal clinical signif-
icance. While SNPs within the CYP3A4 gene may con-
tribute to inter-individual differences, they occur at low
population allele frequencies and are not reported to affect
the pharmacokinetics and/or pharmacodynamics of
CYP3A4 substrates in a major way [64]. However, while
being extremely rare (\0.06 % in Caucasians) [65], the
CYP3A4*20 variant was recently identified in a cohort of
eight patients who had experienced severe paclitaxel-in-
duced neuropathy, which is known to be dose dependent
[66]. Using WES, two patients were found to have the rare
CYP3A4*20 allele, a premature stop codon that leads to an
abnormally shortened protein, and one patient had a
CYP3A4*25 variant, a missense mutation causing the
substitution of a different amino acid in the resulting pro-
tein. Both variants confer significantly reduced CYP3A4
expression. Analysis of DNA from an independent cohort
of 228 patients treated with paclitaxel indicated a 1.3- to
2.0-fold increased risk of paclitaxel-induced neuropathy in
patients carrying CYP3A4 variants that reduced enzyme
expression compared with wild-type CYP3A4 [66].
A related enzyme, CYP3A5, is considered to have
similar substrate specificity to CYP3A4. However, it is
subject to more polymorphisms. Only the CYP3A5*1 (WT)
allele is recognised as functional, the remaining CYP3A5
variants (*2–*11) are non-functional. With respect to
clinical significance, differences in tacrolimus [67] con-
centrations were reported in subjects with the CYP3A5*3
variant compared with those with CYP3A5*1 and it was
concluded that a higher dose of the drug may be required to
maintain optimal blood concentrations in expressors of the
functional variant [67].
Atorvastatin is a substrate for CYP3A5. Evidence that
CYP3A5 polymorphisms are clinically important in the
metabolism of this drug is conflicting but in an exploratory
analysis of patients with atorvastatin-related myopathy, the
CYP3A5*3 allele was associated with the degree of serum
creatine kinase (CK) elevation [68].
3.3 CYP2C9
The enzyme CYP2C9 metabolises approximately 15 % of
all clinical drugs including some oral hypoglycaemics,
nonsteroidal anti-inflammatory drugs, diuretics,
antiepileptic drugs, angiotensin converting enzyme
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inhibitors and, in particular, several drugs with a narrow
therapeutic index such as warfarin (S-warfarin) and
phenytoin [64]. Two commonly occurring missense muta-
tions in the CYP2C9 gene,*2 and *3, decrease enzyme
function by 30 and 90 %, respectively. Two large, recent
randomised controlled studies applied rapid turnaround
CYP2C9 genotyping tests to assess the benefits of geno-
type-guided dosing of warfarin. Pirmohamed et al. con-
cluded that genotyping (CYP2C9*2, CYP2C9*3) prior to
initiation of warfarin therapy resulted in a significantly
(P\ 0.001) greater number of patients remaining within
the target therapeutic range and significantly (P\ 0.001)
fewer incidences of over-anticoagulation, defined as an
international normalized ratio (INR)[4 [69]. However, a
similarly designed trial, the Clarification of Optimal Anti-
coagulation through Genetics (COAG) trial did not show
any benefit of genotype-guided dosing [70]. Similarly,
various meta-analyses have reported mixed results. For
example, a meta-analysis of nine trials conducted in
2001–2013 concluded that there was no significant clinical
benefit of genotype-guided warfarin dosing on either time
in the recommended therapeutic range or the risk of an
INR[4. The authors noted that the nine trials used dif-
ferent genotyping methods as well as different genotype-
based warfarin dosing algorithms, which may have resulted
in skewed outcome definitions [71]. However, a further
meta-analysis of 10 studies concluded that genotype-based
dosing of warfarin increased the percentage of time in the
therapeutic range and reduced the risk of haemorrhagic
complications [72]. CPIC guidelines on genotype-guided
warfarin dosing were last published in 2011 [73], and are
currently under review based on the findings discussed
above. The guidelines published in 2011 recommended the
use of genetic-guided algorithms available on http://www.
warfarindosing.org. Dosing algorithms taking genetics into
account outperform non-genetic algorithms [73].
Polymorphisms in CYP2C9 have also been associated
with phenytoin ADRs. Chung et al. used a GWAS to
investigate genetic variants associated with phenytoin-re-
lated severe cutaneous adverse reactions. They discovered
a cluster of 16 SNPs within the CYP2C gene locus [74]
associated with phenytoin-related ADRs. Further
sequencing of alleles in this region identified a significant
association between the missense variant rs1057910
(CYP2C9*3) and the severe forms of phenytoin-related
cutaneous adverse reactions often referred to as SCARs
This SNP-ADR association was then validated through
analysis of further samples from 210 patients with pheny-
toin-related SCARs and 3655 controls, and an odds ratio of
11.0 (95 % confidence interval 6.2–18.0, P\ 0.00001)
was reported [74]. Delayed plasma clearance of phenytoin
was detected in patients with SCARs, especially
CYP2C9*3 carriers.
3.4 CYP2C19
The enzyme CYP2C19 is known to metabolise 10 % of all
commonly used medicines including proton pump inhibi-
tors, tricyclic antidepressants, SSRIs, SNRIs, barbiturates,
and the antiplatelet drugs clopidogrel, ticlopidine, and
prasugrel. The CYP2C19 gene has at least 24 known
variants with CYP2C19*2 and CYP2C19*3 the major
polymorphisms resulting in poor metaboliser status and
CYP2C19*17, a polymorphism resulting in increased
CYP2C19 expression and activity [64]. There is substantial
literature on the association between CYP2C19 poor
metaboliser status and diminished response to clopidogrel,
and therefore an increased risk of further cardiovascular
events [75]. As clopidogrel is a prodrug it requires bio-
transformation to its active form in the liver by CYP2C19,
CYP1A2 and CYP2B6. A GWAS (Pharmacogenomics of
Antiplatelet Intervention) reported an association with 13
SNPs in the genomic region where the CYP2C18-
CYP2C19-CYP2C9-CYPC8 genes are located [76]. Further
analysis showed that the variant rs12777823 was strongly
correlated with the CYP2C19*2 variant, and was associated
with a greater number of cardiovascular events or death
within 1 year of follow-up (20.9 %) compared with con-
trols (10 %) [76].
Meta-analyses of randomised clinical trials evaluating
CYP2C19 genotype status and the increased risk of sec-
ondary cardiovascular events have reported mixed results.
Mega et al. conducted a meta-analysis of nine studies
incorporating 9685 patients who had undergone percuta-
neous intervention and/or had acute coronary syndrome
[77]. In the population studied, 71.5 % were non-carriers
(i.e., CYP2C19 WT), 26.3 % had one reduced function
allele (*2 or *3), and 2.2 % had two reduced functional
alleles. The authors reported a significantly increased risk
of major cardiovascular events, particularly stent throm-
bosis in patients with one (P\ 0.0001) or two
(P = 0.001) CYP2C19 reduced function alleles [77].
Similarly, Hulot et al. reported that CYP2C19*2 allele
was associated with a 30 % increased risk of a major
cardiovascular event and increased mortality in patients
on clopidogrel therapy. Like the previous study, subjects
with either heterozygote or homozygote CYP2C19*2
alleles were adversely affected [78]. However, two further
meta-analyses have reported that the genetic association
between CYP2C19 genotype and clinical efficacy of
clopidogrel is not consistent or substantial enough to
recommend genotyping prior to therapy [79, 80]. The
CPIC guidelines for clopidogrel indicate that clinicians
should consider alternative anti-platelet agents (prasugrel
or ticagrelor) in patients genotyped to be CYP2C19
intermediate (*1/*2, *1/*3, *2/*17) or poor (*2/*2, *3/*3
or *2/*3) metabolisers [81].
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4 Phase II Enzymes
Polymorphisms in genes for phase II DMEs are a further
source of variation in drug response. Polymorphic phase
two DMEs include N-acetyl transferase type 2 (NAT2)
associated with isoniazid toxicity; thiopurine methyltrans-
ferases (TPMT) associated with thiopurine toxicity; dihy-
dropyrimidine dehydrogenase (DPD) associated with
5-fluorouracil toxicity, and uridine diphosphate-
glucuronosyl transferases (UGT) associated with irinotecan
toxicity [82, 83]. TPMT and NAT2 are discussed below
and DPD and UGT are summarised in Table 2.
4.1 TPMT
Depending on ethnicity, it is estimated that one in 150–300
individuals carry two deficient TPMT alleles resulting in
lack of TPMT activity [84]. As TPMT catalyses the
s-methylation of thiopurine drugs, which are highly toxic
and have a narrow therapeutic index, accumulation of
parent drug and/or metabolites can lead to thiopurine tox-
icity in haematopoietic tissues [14, 85]. Expression of non-
functional and/or reduced function alleles (Table 3) has
been associated with a range of adverse events ranging
from cessation of therapy in up to 25 % of patients to
severe and life-threatening myelosupression [86–88].
CPIC have published guidelines on the prescribing of
three drugs (azathioprine, mercaptopurine and thioguanine)
known to be influenced by TPMT polymorphisms [89].
The CPIC guidelines indicate that pre-emptive TPMT
genetic testing can provide customised dosing to reduce the
likelihood of serious and fatal ADRs such as myelosu-
pression [88, 90, 91]. A recent retrospective study con-
ducted in a French university hospital concluded that pre-
emptive TPMT genotyping improved non-compliance and
allowed the identification of patients at high risk of toxicity
[92].
4.2 NAT
N-Acetyltransferase enzymes, NAT1 and NAT2 metabolise
and detoxify therapeutic drugs through acetylation.
Notably, variability in response to the antituberculosis drug
isoniazid is associated with polymorphisms in the NAT2
gene [93]. Phenotypically, NAT2 polymorphisms confer
either slow or fast acetylator status. Slow acetylators, often
expressing two reduced function and/or inactive alleles, are
reported to be at a greater risk of isoniazid toxicity, par-
ticularly DILI and peripheral neuropathy. In contrast, fast
acetylators are likely to show reduced efficacy [93, 94].
Several retrospective studies have sought to determine
whether genotyping of NAT2 status may have prevented
isoniazid induced toxicity. One such study conducted by
Ng et al. genotyped 26 patients with a history of liver
injury as a result of a drug regimen containing isoniazid.
Patients and ethnically matched controls were genotyped
for three major NAT alleles (NAT2*5, NAT2*6 and
NAT2*7), and it was observed that NAT2 genotypes pre-
dictive of slow acetylator phenotype were associated with
an increased risk of isoniazid-induced DILI [95]. Azuma
et al. also showed that NAT2 genotype-based dosing of
isoniazid compared with standard treatment was beneficial.
The clinical trial showed that with genotype-guided dosing
there were no cases of isoniazid-induced DILI amongst
slow acetylators, compared with 78 % of slow acetylators
in the standard treatment group. With respect to fast-
acetylators and treatment failure, genotyping resulted in a
lower incidence of treatment failure (15 %) when com-
pared with the standard treatment group (38 %) [96].
4.3 Drug Transporters
Polymorphisms also affect transporters and therefore drug
distribution. For example, polymorphisms in the organic
anion transporting polypeptides, also referred to as the
solute carrier organic anion transporters (SLCOs), are one
of the most discussed polymorphisms known to affect the
transport (influx) of statins, and hence impaired efficacy
and/or toxicity [97–99]. Two SNPs in the SLCO1B1 gene,
rs2306283 and rs4149056 are associated with statin-asso-
ciated myopathy [100]. These variants were initially
identified through a GWAS conducted on the SEARCH
(Study of the Effectiveness of Additional Reductions in
Cholesterol and Homocysteine) cohort of 80 confirmed
Table 2 DPD and UGT
variants implicated in
chemotherapy toxicity





Fluoropyrimidine Diarrhoea, mucositis, neutropenia (Grade 3–4)
UGT [164] rs34815109 Irinotecan Diarrhoea, myelosuppression, neutropenia
ADR adverse drug reaction, DPD dihydropyrimidine dehydrogenase, UGT uridine diphosphate-
glucuronosyl transferases
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cases of myopathy and 90 controls [36]. Further GWAS of
similar cohorts such as GoDARTs (Genetics of Diabetes
Audit and Research in Tayside) and STRENGTH (Statin
Response Examined by Genetic Haplotype Markers) have
replicated the results. The composite endpoint was any
adverse effect that led to discontinuation or myalgia or
serum creatine kinase level more than three times the upper
limit of normal. For this endpoint there was a gene–dose
effect relationship with 19, 27 and 50 % of patients
affected with no, one or two SLCO1B1*5 alleles respec-
tively [101, 102]. Interestingly, the association of
rs4149056 with statin-induced myopathy has only been
clearly established for simvastatin [100].
Further studies have identified polymorphisms in other
drug transporters such as the ATP-binding cassette family
(ABC), specifically ABCB1 and ABCG2, which are efflux
transporters that modulate intestinal drug absorption and
tissue penetration [103] and have been associated with
statin-induced muscle myopathy as shown through eleva-
tions in plasma creatine kinase measurements. As expec-
ted, adverse reactions to a range of drugs (Table 4) have
been linked with transporter polymorphisms, mainly by
way of candidate gene association studies.
Zolk and Fromm also identified polymorphisms in four
genes, SLCO1B1, SLC22A2, ABCB11 and ABCB1, which
are associated with increased susceptibility to ADRs in
general [104].
5 Pharmacodynamic Responses
5.1 Drug-Induced Long QT Syndrome
Long QT syndrome (LQTS) is a condition with symptoms
of syncope, seizures and often fatal ventricular arrythmias
of the torsade de pointes type. Initially, by studying
patients with congenital LQTS, genes that code for sodium
and potassium ion channels within cardiomyocytes were
implicated in the disorder [105]. The first mutations in the
potassium channel genes KCNQ1 and KCNH2 (HERG) and
the SCN5A cardiac sodium channel gene (originally named
LQT1, LQT2 and LQT3 respectively), were first discovered
in the 1990s [106]. Individuals with drug-induced (also
referred to as acquired) LQTS present with the same
symptoms and are often carriers of KCNH2 or SCN5A
mutations [105, 106]. Various drug classes (antibiotics,
antipsychotics, chemotherapeutics, antiemetics, opioid
analgesics and anti-arrhythmics) have been associated with
drug-induced LQTS [107]. The association of KCNH2 and
SCN5A mutations with LQTS has been confirmed through
four major GWAS published in the last decade [108–111].
Recently, Weeke et al. identified, through whole exome
sequencing, rare amino acid coding variants that further
increase the risk of drug-induced LQTS. There were more
unique or rare amino acid coding variants (37 %) in a
cohort of 65 patients with previously confirmed drug-in-
duced LQTS compared with 148 (21 %) drug-exposed
controls [112]. Similarly, Ramirez et al. have used NGS
methodology to assess the presence of rare variants in a
cohort of patients with drug-induced LQTS. It was reported
that 11 of the 31 patients carried a novel missense mutation
that matched a known congenital LQTS mutation [113].
5.2 Warfarin and Vitamin K Epoxide Reductase
Complex
Warfarin exerts its anticoagulant effect by inhibiting the
vitamin K epoxide reductase complex, subunit 1
(VKORC1), part of an enzyme that had long been sought as
a target of warfarin but for which the gene was not iden-
tified until 2004 [114]. The identification of this enzyme, as
well as linkage studies carried out in warfarin-resistant rat
strains, rapidly led to identification of variants in the
VKORC1 gene, which impacted on warfarin response
[115], and in some patients, warfarin resistance [116].
The missense mutations CYP2C9 *2 and *3 and the
VKORC1 variants identified are evidence of a combined
effect of pharmacogenes influencing both the pharma-
cokinetics and pharmacodynamics of a medicine. GWAS
initially confirmed the role of these two genes [38] and
revealed an additional gene, CYP4F2, with a minor role
[39].
5.3 HLA Locus
The HLA, also known as the human major histocompati-
bility complex (MHC), is a family of over 200 genes that
are located close together on chromosome 6. The MHC
genes are categorised into three classes, of which class I
(HLA-A, HLA-B and HLA-C genes) and class II (HLA-
Table 3 TPMT functional
alleles
Functional status Alleles
Normal and or wild type *1, *1S
Non-functional, or mutation resulting in no activity *2, *3A, *3B, *3C, *4
Reduced function or decreased activity *5, *6, *8, *9,*10, *11, *12, *13, *16, *17, *18.
TPMT thiopurine methyltransferase
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DPA1, HLA-DPB1, HLA-DQA1, HLA-DRA and HLA-
DRB1) are relevant to this review (Fig. 3).
It is estimated that up to a third of drug-induced ADRs
are unpredictable hypersensitivity reactions, i.e. Type B
ADRs [117, 118], and a large proportion of these are
mediated through the interaction of the drug and/or
metabolite with HLA proteins. Importantly, this interaction
only occurs when specific HLA alleles are present [118,
119]. The HLA-drug (hapten) complex can go on to elicit
an immune response. One mechanism proposed is presen-
tation of the hapten to a naı¨ve lymphocyte via its T-cell
receptor, which may initiate an immunological response
dependent on the HLA molecule, antigen-presenting cell
and cytokine environment [118].
One HLA–ADR association with considerable clinical
utility is that of the haplotype (group of alleles) called
HLA-B*5701 and hypersensitivity to the antiretroviral drug
abacavir [120]. This was originally described by two
groups who essentially used a candidate gene approach, by
careful HLA typing of subjects who experienced the
hypersensitivity reaction and recognition that a specific
haplotype of HLA-B was over represented in this group
[120, 121]. DNA tests for HLA-B*5701 alleles are now
widely employed before prescription of abacavir [122,
123].
More recently, application of GWAS methodology has
revealed other associations of drug hypersensitivity with a
range of HLA alleles. The strongest pharmacogenetic
associations have been reported for flucloxacillin-associ-
ated hepatotoxicity (also referred to as DILI) with HLA-
B*5701, carbamazepine-induced Stevens-Johnson syn-
drome (SJS)/toxic epidermal necrolysis (TEN) with HLA-
B*1502 in Han Chinese, allopurinol-induced severe cuta-
neous ADRs with HLA-B*5801 in Han Chinese and
abacavir-induced hypersensitivity syndrome with HLA-
B*5701 [118, 124].
In the case of carbamazepine-induced SJS, Chung et al.
showed complete penetrance of the HLA-B*1502 allele, i.e.
all individuals with the mutation exhibited SJS, giving a
positive predictive value of 93.6 %. In this particular study
of Han Chinese, 100 % of the cohort of 44 patients
expressed the HLA-B*1502 allele in comparison to 3 % in
Table 4 Transporter polymorphisms (modified from [104])
Transporter Gene (rs numbers) Drugs ADRs




SLC22A1 (rs12208537, rs34130495, rs35167514,
rs34059508)
SLC22A2 (rs316019)
Metformin, cisplatin Hyperlactacidemia nephrotoxicity, ototoxicity
ABC ABCG2 (rs2622604, rs2231137) Irinotecan Myelosuppression





OAT1 SLC22A6 (rs11568626, rs4149170) Antiviral drugs Nephrotoxicity
MRP2 ABCC2 (rs2273697, rs3740066 Irinotecan,
methotrexate
Diarrhoea, nephrotoxicity
ADRs adverse drug reactions
Fig. 3 Location and structure of the human leukocyte antigen (HLA)
locus. The large cluster of genes that comprise the major histocom-
patibility complex (MHC) is located on the short arm of chromosome
6. This region includes some 240 genes and spans some 3.6 million
base pairs of DNA. The class I and class II genes are most relevant for
adverse drug reactions. There are three main class I genes, called
HLA-A, -B and -C, and the class II region includes the genes for the a
and b chains of the antigen-presenting MHC class II molecules HLA-
DR, -DP, and -DQ
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the carbamazepine-tolerant population (3/101) and 8.6 %
in the general Han Chinese population (8/93) [125]. For
flucloxacillin-induced DILI, a GWAS (the DILIGEN
study) conducted in 51 cases and 282 controls showed that
the rs2395029 SNP was significantly associated with flu-
cloxacillin-induced DILI. The SNP was confirmed to be in
linkage disequilibrium with the HLA-B*5701 allele, and
carriers of this polymorphism were at 80-fold greater risk
of developing flucloxacillin-induced DILI. Unlike the
previously discussed HLA allele (HLA-B*1502), which
was common in the Han-Chinese population, HLA-B*5701
has a high allelic frequency in northern European popula-
tions when compared with African or Asian populations
[37]. Other ADRs associated with the HLA locus derived
from GWAS are listed in Table 5.
Other genetic associations of HLA alleles with ADRs
were recognised as early as the 1990s. For example,
clozapine-induced agranulocytosis has been associated
with haplotypes of HLA-B38, HLA-DR4 and HLA-DQ3
[126]. Recently, WES and GWAS methods have identified
an association between clozapine-induced agranulocyto-
sis/granulocytopenia and the HLA-DQB1 and HLA-B alle-
les. This latest study by Goldstein and colleagues confirms
previous studies [127–129] and provides further evidence
to attribute the association to two amino acids, a glutamine
at position 126 of HLA-DQB1, and a threonine at position
158 of HLA-B [130]. Furthermore, the authors used
molecular docking to show that clozapine binds with high
affinity to the HLA-B*39 antigen-presenting peptide.
Docking studies showed that clozapine had low affinity for
HLA-A proteins. However, the authors noted that the set of
variants identified may not be robust enough to identify a
‘‘safe-clozapine’’ group, as the sensitivity and specificity
was low (0.36 and 0.89, respectively) [130].
With respect to thiopurine drugs (azathioprine or mer-
captopurine), pancreatitis is an unpredictable ADR
reported to occur in up to 4 % of patients. A recent study
identified an association between azathioprine and mer-
captopurine-induced pancreatitis with two HLA alleles
(HLA-DQA1*02:01–HLA-DRB1*07:01 haplotype) in the
class II region. It was reported that patients heterozygous
for a specific SNP (rs2647087) had a 9 % risk of devel-
oping pancreatitis, whereas homozygotes had a 17 % risk
[131].
HLA genotyping prior to the commencement of carba-
mazepine or allopurinol prescription is becoming an
indispensable tool to prevent ADRs in patients of south-
east Asian descent. In fact, several drugs now have updated
safety labels, or boxed warnings recommending HLA
genotyping prior to drug prescription [132–134]. CPIC
guidelines are currently available for four drug-induced
ADRs with HLA allele associations, allopurinol-HLA-
B*5801, carbamazepine HLA-B*1502, abacavir-HLA-
B*5701 and phenytoin-HLA-B*1502 [59].
6 ADRs Determined by Multiple Pharmacogenes
By grouping genotypes according to their kinetic, dynamic
or immunological influences on the development of ADRs
there is the danger of not seeing the complexity of the
genetic influences that may lead to the development of one
ADR. Recent studies have revealed some hitherto unex-
pected associations which identify more than one phar-
macogene associated with a single ADR. As previously
discussed, algorithms generated from warfarin dosing
studies and GWAS have identified variants of CYP2C9 and
VKORC that demonstrate clinical utility in warfarin dosing
[39].
Similarly, the association between CYP2C9*3 and
phenytoin-related severe cutaneous adverse reactions dis-
covered by a GWAS is unlikely to be a complete
Table 5 Genome-wide
association studies on ADRs
associated with the HLA locus
Drug Gene ADR Odds ratio
Ximelagatran [157] HLA-DRB180701 DILI 4
Lumiracoxib [158] HLA-DQA1*0102 DILI 5
Flucloxacillin [37, 159] HLA-B*5701 DILI 81
HLA-DRB1*0107
HLA-DQB1*0103 7




Abacavir [120] HLA-B*5701 Hypersensitivity syndrome 33
Sulfomethoxazole [161] HLA-B*3802 SJS 76
Allopurinol [162] HLA-B*5801 SJS 580
ADRs adverse drug reactions, DILI drug-induced liver injury, SJS Stevens-Johnson syndrome, HLA human
leukocyte antigen
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explanation because these reactions have immunological
characteristics. In a study by Chung et al., an association
between HLA-B*1502 and phenytoin-related SJS/TEN was
also shown. Chung et al. proposed that interplay between
delayed clearance and the accumulation of reactive
phenytoin metabolites due to genetic variants of DMEs
together with individual immunogenicity might facilitate
the development of phenytoin-related cutaneous adverse
reactions [64]. The CPIC guidelines recommend at mini-
mum, a 25 % reduction in the starting dose of phenytoin in
CYP2C9 intermediate metabolisers, and at minimum, a
50 % reduction in phenytoin dose in poor metabolisers.
Additionally, regardless of CYP2C9 status, the CPIC
guidelines recommend using an anticonvulsant other than
carbamazepine or phenytoin if the patient is a carrier of
HLA-B*1502 unless the benefits of treatment outweigh the
risks of developing SJS/TEN [135].
Statins are another group of drugs known to have a
number of pharmacogenes associated with altered drug
disposition [136]. Statins are associated with myopathy,
ranging in severity from asymptomatic increases in cre-
atine kinase to myalgia or muscle weakness, to fatal
rhabdomyolysis. Even the less serious forms can lead to
non-adherence. However, members of this therapeutic
group vary in their degree of lipophilicity and metabolic
pathways. Recently, concerns have been raised about a
disproportionate increase in the risk of myopathy with
high-dose simvastatin. As discussed, for statins, SLCO1B1
variants affecting SLCO influx transporter activity appear
to be the most important genetic determinants for the
development of myopathies, although the strongest evi-
dence is for simvastatin [36, 101, 137]. There is also evi-
dence of a contribution from polymorphisms in the ABCB1
and ABCG2 efflux transporter genes. Surprisingly for the
statins, which are substrates for CYP3A4 and 5 enzymes,
the evidence that variants of CYP3A4 and 5 may contribute
to myopathy is not conclusive and may vary between sta-
tins. An interesting development comes from a study which
reported potential protection against statin-related myopa-
thy through a variant (rs1719247) of the gene for the gly-
cine amidinotransferase (GATM) mitochondrial enzyme
that catalyses the rate-limiting step in the biosynthesis of
creatine. This hypothesis was tested in two groups of
patients with a resulting meta-analysis odds ratio of 0.6
(95 % confidence interval 0.45–0.81) for the association of
this GATM SNP with myopathy [138].
The finding that the strongest relationship between
SLCO1B1*5 and statin-related myopathy is for simvastatin
is interesting and has practical implications as a study of
clinical trial data and reported ADRs concluded that high-
dose simvastatin (80 mg daily) carries a greater risk of fatal
myopathy than 80 mg atorvastatin and lower doses of
rosuvastatin. Because the SEARCH study did not
demonstrate a difference in the development of cardio-
vascular events between low- and high-dose simvastatin,
the US Food and Drug Administration advised that sim-
vastatin 80 mg daily should not be prescribed for patients
who had not already tolerated it for a year, and that alter-
native agents should be used if lipid targets could not be
reached with lower doses of simvastatin [139].
Recently, there have been reports of patients expressing
autoantibodies to the HMG-CoA reductase enzyme which
results in immune-mediated myositis and necrotising
myopathy. In a recent study of patients with idiopathic
inflammatory myopathy, the presence of anti-HMGCR
antibodies was significantly (P\ 0.0001) associated with
statin exposure and HLA-DRB1*11 [140].
Last, it is important to note that patients may sometimes
carry novel variants that affect drug disposition. For
example, a recent study described the whole-gene
sequencing of CYP2D6 and CYP2C19 in a patient with
severe adverse effects to venlafaxine or combined therapy
with nortriptyline and fluoxetine. Chua et al. identified one
novel mutation in the CYP2D6 gene and three novel
mutations in the CYP2C19 gene, meaning the function of
both genes was compromised hence providing an expla-
nation for their reported adverse effects to anti-depressants
[141]. This case reinforces the notion that rare genetic
variants, often not previously reported, are likely to have
more substantial phenotypic effects than common variants.
Had traditional genetic testing solely of ‘‘known’’ common
variants [142] been conducted in this case, the patient may
have been incorrectly classified as having intermediate
CYP2D6 metabolic status, and normal CYP2C19 function.
Although this study was conducted with Sanger sequenc-
ing, NGS methods make the wider analysis of all relevant
variation in pharmacogenes, beyond solely the common
variants, a much more accessible prospect.
7 Limitations of Using Genome Sequencing
in Clinical Decision Making
As pharmacogenetic testing makes its way into the clinical
setting, it is not likely to entirely displace standard thera-
peutic drug monitoring or measurement of other pheno-
typic variables for narrow-therapeutic index drugs or drugs
intended for the treatment of life-threatening diseases, such
as azathioprine, phenytoin and warfarin. The concordance
between genotype and phenotype is not absolute as the
phenotype can be influenced by other factors such as drug–
drug interactions, age, sex and co-morbid conditions [143].
For example, azathioprine-treated patients are at risk of
dose-dependent myelosuppression. Neither pre-emptive
TPMT genotyping nor phenotyping by enzyme activity in
red blood cells can be regarded as sufficiently predictive
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methods. However, they can be complementary [144].
Identifying patients with null TPMT activity through
genotyping (TPMT*3 and TPMT*2) can identify up to
95 % of such patients but this concordance rate drops to
86 % when classifying patients with intermediate enzyme
activity. The results of genotyping can be used to make
recommendations about azathioprine avoidance or dose
reductions. However, it is important to note that the TPMT
genotype is not the sole reason for increased risk of
myelosuppression in patients taking azathioprine and
determining TPMT enzyme activity and/or monitoring of
6-thioguanine nucleotide concentrations is still recom-
mended [145, 146].
Phenoconversion, the transient conversion of genotypic
extensive metabolisers to phenotypic poor metabolisers, is
a phenomenon that needs to be considered in the context of
genotype/phenotype concordance. Phenotypic changes
may occur during the course of treatment because of co-
prescription of other interacting drugs [147]. Phenocon-
version has also been clinically associated with elevated
cytokines present during inflammatory disease states. Shah
and Smith have summarised probe studies showing rates of
phenoconversion of genotypic CYP2D6 EMs to phenotypic
PMs for various CYP2D6 inhibitors. They also discuss co-
morbidities and present evidence for conversion of geno-
typic EMs to phenotypic PMs because of reduced
CYP2D6, NAT2 and CYP3A4 activity in some human
immunodeficiency virus-infected patients, and reduced
CYP2C19 activity in studies of patients with liver disease
or advanced cancer [147, 148].
8 Conclusion: Personal Genomes and the Future
of Pharmacogenetic Testing
It is clear that application of new genetic technologies is
enhancing our understanding of pharmacogenetics, and
clarifying the genetic underpinnings of various ADRs.
Although many ADRs are likely to be complex pheno-
types, resulting from interactive effects of numerous
genetic susceptibility alleles and environmental factors, a
surprising range of ADRs appear to have a less complex
genetic basis, and in many demonstrated cases, only one or
a few genes appear to largely determine susceptibility to
the specific ADR.
Clarification of genetic susceptibility factors for ADRs
is clearly of fundamental importance, and such knowledge
extends our understanding of pharmacology, genetics and
immunology. Beyond such intrinsic value, however, will it
ever be possible to routinely apply such knowledge to
predict and prevent occurrence of ADRs? Given the rarity
of many relevant gene variants, the relatively slow turn-
around times and costs of conventional tests (if they are
even accessible), and often limited evidence base to sup-
port the clinical utility of predictive testing, it is unlikely
that many of the genetic variants described in this review
could currently be used to predict likelihood of an ADR
(within the conventional testing paradigm). However,
genomic medicine is moving apace, and the application of
NGS methods, including WES and WGS, is being explored
in many areas [45, 149–151] with a number of centres
evaluating the prospective application of high-throughput
pharmacogenetic analysis, with decision support, in the
hospital setting [152, 153]. It is foreseeable that a single
NGS test spanning all clinically actionable genotypes,
including those relevant to drug responses, could be
established [154, 155]. Such a test would need to be carried
out only once, and it could include variants that are rare
and therefore uneconomic to test for in a traditional diag-
nostic pathology setting. Establishment of such a genome-
based test will require resolution of many problems, par-
ticularly relating to Mendelian disease, such as the man-
agement of incidental findings, the problem of assigning
function to novel variants, and storage and management of
the data. However, it is conceivable that such a test could
provide information on all variants likely to impact on
pharmacokinetics and ADRs, in an affordable format. An
important interim step on the path to such a goal, therefore,
is to build an extensive and robust evidence base for all
genetic factors that may contribute to good or bad drug
responses.
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